

StemRIM Announces Exhibiting at the "BIO International Convention 2023" and Participating in the "Jefferies 2023 Global Healthcare Conference New York"

Osaka, Japan, June 1, 2023 – StemRIM Inc. (TSE: 4599, Chairman and CEO: Kensuke Tomita; "StemRIM") announced today, exhibiting as part of the Japan Pavilion organized by the Japan External Trade Organization (JETRO) at the "BIO International Convention 2023" held in Boston, USA from June 5th to 8th, 2023 and participating in the "Jefferies 2023 Global Healthcare Conference New York" held in New York, USA from June 7th to 9th, 2023.

The "BIO International Convention 2023" is the world's largest business partnering event, gathering over 14,000 biotechnology and pharmaceutical companies with the aim of exploring new business opportunities and forming promising partnerships. Our company will be participating to license out the next generation of "Regeneration-Inducing Medicine™" following our Redasemtide. We seek to partner with leading pharmaceutical companies worldwide during this event.

The "Jefferies 2023 Global Healthcare Conference New York" is an annual event organized by Jefferies LLC, a global investment bank. This conference brings together healthcare companies, institutional investors, and industry experts to serve as a platform for discussing major trends, developments, and investment opportunities in the healthcare sector.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University to realize a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration.

Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH),

systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

Twitter: [@StemRIM_Inc](https://twitter.com/StemRIM_Inc)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)